Sai Life Science Ltd shares fell over 14% on Friday, May 15, marking the biggest single-day decline since the company's listing in December 2024. According to reports from CNBC TV18, the stock is currently trading 11% lower at ₹990.5 and has emerged as the top loser on the Nifty 500 index. Despite the sharp fall, the contract research firm had delivered impressive annual results, with net profit surging 109% to ₹355 crore in FY26 from ₹170 crore in the previous year. The company's revenue grew 29% to ₹2,192 crore in FY26 from ₹1,695 crore in the previous fiscal, demonstrating strong operational scaling across CRDMO services.
For the March quarter, Sai Life's net profit increased 18.1% to ₹104.24 crore from ₹88.27 crore in the same period last year, as reported by CNBC TV18. However, the sequential growth was modest at 4% compared to the previous quarter. The company's revenue grew 3.9% to ₹602.13 crore from ₹579.5 crore year-on-year, though it showed 8% sequential growth. EBITDA increased 12% to ₹176.54 crore from ₹157.57 crore in Q4 last year, but declined 6% from the December quarter. Total income for Q4FY26 stood at ₹617.66 crore compared to ₹589.11 crore in the corresponding quarter last year, registering growth of around 4.8% year-on-year, mainly supported by higher contribution from contract manufacturing services.
EBITDA margins expanded to 30.1% in FY26 from 25.1% in the year-ago period, according to the latest investor presentation. This represents a substantial improvement from the 29.3% margins reported in Q4 and the 34% margins reported in the previous quarter, demonstrating the company's ability to maintain operational efficiency despite market challenges. The PAT margin improved significantly to 16.2% from 10.0% in FY25, while Return on Capital Employed (ROCE) increased to 18.2% from 12.3% in the previous year. The company benefited from controlled expense growth relative to revenue expansion, with total expenses increasing to ₹478.72 crore in Q4FY26 compared to ₹470.31 crore in Q4FY25, reflecting relatively moderate growth despite higher business activity.
For the complete financial year 2026, Sai Life's net profit increased 109% to ₹355 crore from ₹170 crore in the previous year, as reported by CNBC TV18. The company's revenue grew 29% to ₹2,192 crore in FY26 from ₹1,695 crore in the previous fiscal. EBITDA surged 56% to ₹661 crore from ₹425 crore reported last year, while margins expanded significantly to 30.1% from 25.1% in the year-ago period. Earnings per share (EPS) for FY26 improved significantly to ₹16.63 compared to ₹8.83 reported in the previous financial year. A major development during FY26 was the successful completion of the company's IPO in December 2025, raising approximately ₹950 crore through a fresh issue of shares. The company utilized around ₹72 crore towards repayment or prepayment of borrowings, while the remaining proceeds were allocated toward general corporate purposes.
The company highlighted deepening engagement with global large pharma customers across Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments in its investor presentation. Sai Life Sciences received commercial supply qualification from two additional large pharma customers, expanding its client base and revenue visibility. Integrated discovery services continued to scale, with growing cross-sell opportunities. The company also noted that its Bidar manufacturing sites (Unit IV and Unit VI) have become the first sites of an Indian CRDMO to operate on 100% renewable power, demonstrating commitment to sustainability initiatives. Despite the recent decline, Sai Life Science shares had surged more than 100% from its IPO price of ₹549 and were trading near its 52-week high of ₹1,139 ahead of the current fall, according to CNBC TV18.
